# Brookside Capital

> Brookside Capital is a VC fund backing Biotechnology and Health Care. See 45 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 45
- Last investment: Jan 2016
- Lead investor: 22%
- Last fund: Mar 2016
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/brookside-capital-inc
- Website: http://www.brooksidecapital.com

Brookside Capital is a VC fund in San Francisco focused on Biotechnology and Health Care. They design, implement, and manage custom tailored portfolios of liquid assets for high net worth investors.

## Contacts

5 contacts available for Brookside Capital. Shizune tracks 6 team members at Brookside Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/brookside-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 15 | 33% |
| Health Care | 12 | 27% |
| Therapeutics | 7 | 16% |
| Medical | 6 | 13% |
| Genetics | 6 | 13% |

58 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 10 | 22% |
| Series B | 7 | 16% |
| Series D | 7 | 16% |
| Series E | 4 | 9% |
| Funding Round | 3 | 7% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 28 | 62% |
| China | 2 | 4% |
| Indonesia | 1 | 2% |
| Singapore | 1 | 2% |
| South Korea | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daniel Krizek | Director | 1 | https://shizune.co/investors/profile/daniel-krizek |
| Thomas L. Rea | Board of Advisors | 0 | https://shizune.co/investors/profile/thomas-l-rea |
| Craig Law | Operations Manager | 0 | https://shizune.co/investors/profile/craig-law |
| Doreen Marino | Director of Client Services | 0 | https://shizune.co/investors/profile/doreen-marino |
| James Rea | President | 0 | https://shizune.co/investors/profile/james-rea |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Anaplan | Anaplan is driving a new age of connected planning. Large and fast-growing organizations use Anaplan’s cloud platform in every business function to make better-informed plans and decisions and drive faster, more effective planning processes. Anaplan also provides support, training, and planning transformation advisory services. Anaplan is aprivately held company based in San Francisco with 16 offices and over 150 expert partners worldwide. To learn more, visit anaplan.com. | $90M | Series E | Jan 16, 2016 |  |
| Socar | Socar is a Korean eco-friendly car sharing community that allows travelers to share cars with others who are traveling the same route.Socar has raised an $18 million round of funding in 2015 which was one of the highest funding deals for a South Korean startup to date. Most notably, it was led by a US investor: Bain Capital, a private investmentfirm with $80 billion in assets under management.Socar was founded in March 2012, and it has a website and smartphone apps that let users book cars for their own use. Service has over 1,700,000 registered users, 50,000 of whom use the service each month. Around 80,000 transactions per month — that’s more than one car booking each 30 seconds. | $48.3M | Series B | Nov 27, 2015 |  |
| SevOne | SevOne provides the only digital infrastructure performance monitoring solution engineered for Speed at Scale for the world’s most demanding service-delivery environments. The patented SevOne ClusterTM architecture leverages distributed computing to monitor any device in the service-delivery path, integrating performance metrics, flows, and logs atscale, while providing answers in seconds to prevent performance-impacting outages. SevOne’s global customer base includes 5 of the 7 top global investment services companies, enterprises, CSPs, MSPs and MSOs. SevOne serves organizations that are looking to complex, dynamic next-generation infrastructure such as software=defined networks, orchestrated containers, and cloud technologies to support their business goals. The company is backed by Bain Capital Ventures and was named a Visionary in Gartner’s 2015 Magic Quadrant for Network Performance Monitoring and Diagnostics. | $47.1M | Series C | Sep 23, 2015 |  |
| Translate Bio | Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases. Translate Bio is a therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.The company was founded in 2011 and headquartered in Lexington,Massachusetts. | $63.8M | Series B | Jul 23, 2015 |  |
| Giosis | Giosis, the company behind Qoo10, operates an e-marketplace offering sellers customisable sales strategies and buyers an extensive product portfolio. It is a joint venture established between eBay Inc. and Gmarket Inc. founder, Mr Ku Young Bae, in April 2010. Today, Giosis provides seven localised marketplaces, Qoo10, in five countries – China,Hong Kong, Japan, Indonesia, Malaysia and Singapore. It partners esteemed enterprises such as Mecox Lane and Yahoo to enable e-commerce of the best deals in almost every country. Qoo10’s five markets transacted SGD278 million in 2012, almost doubling 2011's SGD150 million. In Singapore, its daily transactions are about 30,000, translating into monthly sales volume of SDG15 million and annual sales volume of SGD90 million in 2012. As of January 2013, 960,000 Qoo10 mobile apps have been downloaded across the five Qoo10 e-marketplaces. Singapore contributed some 580,000 downloads. About 20 per cent of the overall sales come from mobile sales, and this number is expected to rise to 30 per cent within 2013.As of March 2013, there are about 50,000 registered sellers on Qoo10 Singapore. About 150 sellers transact at least SGD10,000 every month. There are about 900,000 registered users on Qoo10 Singapore. More than 1,000 new users are registered on Qoo10 Singapore every day since January 2012. | $82.1M | Series A | Jul 23, 2015 |  |
| Qoo10-Indonesia | PT.Giosis(Qoo10) is founded as a joint venture with eBay; the world’s largest ecommerce service provider, to build a dynamic Pan Asia emarketplace.Giosis Gmarket offers an innovative ecommerce platform providing the customers fun, convenient, price competitive and secure shopping experiences for reliable goods and services from all over theworld.Kalau ada pertanyaan, kamu bisa menghubugi customer service kami di 021-2934-3525 (senin s/d jumat 08.00 s/d 17.00) atau kirim e-mail ke help@qoo10.co.id | $82M | Series A | Jul 20, 2015 |  |
| REGENXBIO | REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologicdisorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia. | $70.5M | Series D | May 20, 2015 |  |
| MuleSoft | MuleSoft makes it easy to connect the world’s applications, data, and devices. They provide a software platform that enables organizations to easily build application networks using APIs. APIs are the digital glue that allows applications to talk to each other and exchange data. Their flexible, unified platform connects nearly any application orsystem by leveraging APIs to quickly and securely share data, regardless of format or source, in application networks.It was founded in 2006 and is headquartered in San Francisco, California,. | $128M | Series G | May 19, 2015 |  |
| Docusign | DocuSign operates a cloud-based electronic signature platform that helps small- and medium-sized businesses, enterprises, and individuals collect information, automate data workflows, and sign on various devices.The company’s platform automates manual and paper-based processes that allow users to manage various aspects of documented businesstransactions, including identity management, authentication, digital signature, forms and data collection, collaboration, and workflow automation and storage.The company also provides training and support services. Its platform serves the sales, human resources, finance, information technology, operations, legal, marketing, facilities, support, product management, and procurement departments in the financial services, healthcare, technology, higher education, insurance, real estate, life sciences, and government sectors in the United States and internationally.DocuSign was incorporated in 2003 and is based in San Francisco, California with additional offices in London, Sydney, Sao Paulo, and Dublin. | $300M | Series F | May 12, 2015 |  |
| Voyager Therapeutics | Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well asprocess development and production.The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass. |  | Series B | Apr 13, 2015 |  |

10 of 45 investments shown.

## Co-investors
- [Sutter Hill Ventures](https://shizune.co/investors/profile/sutter-hill-ventures) — VC Fund, 6 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 5 deals together
- [Maverick Ventures](https://shizune.co/investors/profile/maverick-ventures) — VC Fund, 5 deals together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 5 deals together
- [Skyline Ventures](https://shizune.co/investors/profile/skyline-ventures) — VC Fund, 5 deals together
- [Bain Capital Ventures](https://shizune.co/investors/profile/bain-capital-ventures) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

### Similar country
- [East Ventures](https://shizune.co/investors/profile/east-ventures) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [AC Ventures](https://shizune.co/investors/profile/acventures) — VC Fund

## Featured in investor lists
- [Consumer VC Funds in Indonesia](https://shizune.co/investors/consumer-vc-funds-indonesia)
- [Consumer Investors in Indonesia](https://shizune.co/investors/consumer-investors-indonesia)

## FAQ

### What does Brookside Capital invest in?

Brookside Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series C and Series B stage. Most of the 45 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Brookside Capital?

Public channels for Brookside Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Brookside Capital?

The team at Brookside Capital includes Daniel Krizek (Director), Thomas L. Rea (Board of Advisors) and Craig Law (Operations Manager), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co